RepurpOS

Sarcopenia

Disease intelligence for Sarcopenia: 190 alterations and 82 ranked therapeutics from curated public databases.

US DALYs4.08MWHO GHE 2021 · all ages
Global DALYs45.69MWHO GHE 2021 · worldwide
US mortality12.5K deaths/yrWHO GHE 2021
Global mortality110.0K deaths/yrWHO GHE 2021 · worldwide
NIH funding$37MFY2025 · RCDC estimate
Funding levelSeverely Underfunded

Disease overview

Alterations
190
Molecular (A)
100
Clinical (B–E)
90
Direct drugs
23
Via biomarker
52
Natural agents
8
Natural products
73
Merged ranked
82
With trial/literature evidence
25

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, OSMF Chronic Disease Review, PubMed MeSH, PubMed Literature · Pipeline phase 7 · Updated 2026-07-05

Identifiers: MONDO: MONDO:0002331 · MESH: D055948 · UMLS_CUI: C1837640

Alterations

190 total · Types A (molecular) through E (functional)

NameTypeSubtypeDirection FrequencyEvidenceSourcesLinks
Abdominal distention Pathology Pathological finding — — Moderate HPO, Monarch HPO
Acute kidney injury Pathology Pathological finding — — Moderate HPO, Monarch HPO
Areflexia Pathology Pathological finding — — Moderate HPO, Monarch HPO
Blindness Pathology Pathological finding — — Moderate HPO, Monarch HPO
Cataract Pathology Pathological finding — — Moderate HPO, Monarch HPO
Congenital nephrotic syndrome Pathology Pathological finding — — Moderate HPO, Monarch HPO
Diffuse mesangial sclerosis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Edema Pathology Pathological finding — — Moderate HPO, Monarch HPO
Feeding difficulties Pathology Pathological finding — — Moderate HPO, Monarch HPO
Focal segmental glomerulosclerosis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Fundus hypopigmentation Pathology Pathological finding — — Moderate HPO, Monarch HPO
Gastroesophageal reflux Pathology Pathological finding — — Moderate HPO, Monarch HPO
Global developmental delay Pathology Pathological finding — — Moderate HPO, Monarch HPO
Glomerular sclerosis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Hemolytic anemia Pathology Pathological finding — — Moderate HPO, Monarch HPO
Hemolytic-uremic syndrome Pathology Pathological finding — — Moderate HPO, Monarch HPO
High myopia Pathology Pathological finding — — Moderate HPO, Monarch HPO
Hyperechogenic kidneys Pathology Pathological finding — — Moderate HPO, Monarch HPO
Hypertension Pathology Pathological finding — — Moderate HPO, Monarch HPO
Hypoalbuminemia Pathology Pathological finding — — Moderate HPO, Monarch HPO
Hypoplasia of the ciliary body Pathology Pathological finding — — Moderate HPO, Monarch HPO
Hypoplasia of the iris Pathology Pathological finding — — Moderate HPO, Monarch HPO
Hypoproteinemia Pathology Pathological finding — — Moderate HPO, Monarch HPO
Hyporeflexia Pathology Pathological finding — — Moderate HPO, Monarch HPO
Hypotonia Pathology Pathological finding — — Moderate HPO, Monarch HPO
Macular hypoplasia Pathology Pathological finding — — Moderate HPO, Monarch HPO
Membranoproliferative glomerulonephritis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Mesangial hypercellularity Pathology Pathological finding — — Moderate HPO, Monarch HPO
Microcephaly Pathology Pathological finding — — Moderate HPO, Monarch HPO
Microcoria Pathology Pathological finding — — Moderate HPO, Monarch HPO
Microphthalmia Pathology Pathological finding — — Moderate HPO, Monarch HPO
Microscopic hematuria Pathology Pathological finding — — Moderate HPO, Monarch HPO
Minimal change glomerulonephritis Pathology Pathological finding — — Moderate HPO, Monarch HPO
Motor delay Functional Functional — — Moderate HPO, Monarch HPO
Neonatal respiratory distress Pathology Pathological finding — — Moderate HPO, Monarch HPO
Nephrotic syndrome Pathology Pathological finding — — Moderate HPO, Monarch HPO
Oligohydramnios Pathology Pathological finding — — Moderate HPO, Monarch HPO
Persistent head lag Pathology Pathological finding — — Moderate HPO, Monarch HPO
Podocyte foot process effacement Pathology Pathological finding — — Moderate HPO, Monarch HPO
Posterior lenticonus Pathology Pathological finding — — Moderate HPO, Monarch HPO
Progressive microcephaly Pathology Pathological finding — — Moderate HPO, Monarch HPO
Proteinuria Pathology Pathological finding — — Moderate HPO, Monarch HPO
Remnants of the hyaloid vascular system Pathology Pathological finding — — Moderate HPO, Monarch HPO
Renal insufficiency Pathology Pathological finding — — Moderate HPO, Monarch HPO
Renal tubular atrophy Pathology Pathological finding — — Moderate HPO, Monarch HPO
Retinal detachment Pathology Pathological finding — — Moderate HPO, Monarch HPO
Retinal hemorrhage Pathology Pathological finding — — Moderate HPO, Monarch HPO
Retinal vascular tortuosity Pathology Pathological finding — — Moderate HPO, Monarch HPO
Rieger anomaly Pathology Pathological finding — — Moderate HPO, Monarch HPO
Rod-cone dystrophy Pathology Pathological finding — — Moderate HPO, Monarch HPO
Short stature Pathology Pathological finding — — Moderate HPO, Monarch HPO
Skeletal muscle atrophy Pathology Pathological finding — — Moderate HPO, Monarch HPO
Stage 3 chronic kidney disease Pathology Pathological finding — — Moderate HPO, Monarch HPO
Stage 5 chronic kidney disease Pathology Pathological finding — — Moderate HPO, Monarch HPO
Steroid-resistant nephrotic syndrome Pathology Pathological finding — — Moderate HPO, Monarch HPO
Strabismus Pathology Pathological finding — — Moderate HPO, Monarch HPO
Thickened glomerular basement membrane Pathology Pathological finding — — Moderate HPO, Monarch HPO
Thrombocytopenia Pathology Pathological finding — — Moderate HPO, Monarch HPO
Tube feeding Pathology Pathological finding — — Moderate HPO, Monarch HPO
Uveal ectropion Pathology Pathological finding — — Moderate HPO, Monarch HPO
ACTN4
actinin alpha 4
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ADAMTSL1
ADAMTS like 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
AGXT
alanine--glyoxylate aminotransferase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
AHI1
Abelson helper integration site 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ALG1
ALG1 chitobiosyldiphosphodolichol beta-mannosyltransferase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ANKFY1
ankyrin repeat and FYVE domain containing 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ANLN
anillin, actin binding protein
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
APOL1
apolipoprotein L1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ARHGAP24
Rho GTPase activating protein 24
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ARHGDIA
Rho GDP dissociation inhibitor alpha
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
AVIL
advillin
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
AXDND1
axonemal dynein light chain domain containing 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Adherence to PS (BCAA biomarker) Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
Assessment of muscle strength and performance. 400-meter Walk Test Perfomance (Day 0 and at 6 weeks of intervention). Functional Functional test — — Emerging ClinicalTrials.gov —
Assessment of muscle strength and performance. Grip strength (Day 0 and at 6 weeks of intervention). Functional Functional test — — Emerging ClinicalTrials.gov —
Assessment of muscle strength and performance. Short Physical Performance Battery (Day 0 and at 6 weeks of intervention). Functional Functional test — — Emerging ClinicalTrials.gov —
Assessment of muscle strength and performance. Timed-up-and-go (Day 0 and at 6 weeks of intervention). Functional Functional test — — Emerging ClinicalTrials.gov —
BTC
betacellulin
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Based on the results of empirical research on sarcopenia in Asian countries, a diagnostic consensus was established. Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
Body composition (Day 0 and at 6 weeks of intervention). Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
CACNB2
calcium voltage-gated channel auxiliary subunit beta 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CADPS
calcium dependent secretion activator
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CALHM6
calcium homeostasis modulator family member 6
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CD2AP
CD2 associated protein
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CDC14C
cell division cycle 14C
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CFH
complement factor H
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CHRNA10
cholinergic receptor nicotinic alpha 10 subunit
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CLCN5
Cl-/H+ antiporter 5
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CLEC16A
C-type lectin domain containing 16A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
COL4A3
collagen type IV alpha 3 chain
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
COL4A4
collagen type IV alpha 4 chain
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
COL4A5
collagen type IV alpha 5 chain
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
COQ2
coenzyme Q2, polyprenyltransferase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
COQ6
coenzyme Q6, monooxygenase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
COQ8B
coenzyme Q8B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
CRB2
crumbs cell polarity complex component 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Calf circumference Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
Change in Timed Up and Go Test (TUG) Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
Change in muscle mass Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
Changes in BMI Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
DAAM2
dishevelled associated activator of morphogenesis 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
DGKE
diacylglycerol kinase epsilon
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
DPP10
dipeptidyl peptidase like 10
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
EMP2
epithelial membrane protein 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ENTPD5
ectonucleoside triphosphate diphosphohydrolase 5 (inactive)
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
EYS
EGF-like photoreceptor maintenance factor
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
FAM161B
FAM161 centrosomal protein B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
FAT1
FAT atypical cadherin 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
FKBP1A
FKBP prolyl isomerase 1A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Fat mass Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
Fat oxidation (FatMax) during during half-effort test Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
Functionality Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
GAPVD1
GTPase activating protein and VPS9 domains 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
GLA
galactosidase alpha
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
GRIN2A
glutamate ionotropic receptor NMDA type subunit 2A
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Gait speed Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
Handgrip strength Functional Functional test — — Emerging ClinicalTrials.gov —
IMPDH1
inosine monophosphate dehydrogenase 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
IMPDH2
inosine monophosphate dehydrogenase 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
INF2
inverted formin 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ITGA3
integrin subunit alpha 3
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Insulin sensitivity (HOMA-IR) Lab / Clinical Lab value — — Emerging ClinicalTrials.gov LOINC
Isometric arm flexion strength (Day 0 and at 6 weeks of intervention) Functional Functional test — — Emerging ClinicalTrials.gov —
KANK2
KN motif and ankyrin repeat domains 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
KANK4
KN motif and ankyrin repeat domains 4
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
KIRREL1
kirre like nephrin family adhesion molecule 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
KIRREL2
kirre like nephrin family adhesion molecule 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
LAMA5
laminin subunit alpha 5
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
LAMB2
laminin subunit beta 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
LMX1B
LIM homeobox transcription factor 1 beta
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
MAGI2
membrane associated guanylate kinase, WW and PDZ domain containing 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
MC2R
melanocortin 2 receptor
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
MGMT
O-6-methylguanine-DNA methyltransferase
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
MORC4
MORC family CW-type zinc finger 4
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
MS4A1
membrane spanning 4-domains A1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
MYO1E
myosin IE
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Metabolic flexibility - oxidation of substrates: VO2 peak Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
Muscle mass Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
NOS1AP
nitric oxide synthase 1 adaptor protein
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NPHS1
NPHS1 adhesion molecule, nephrin
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NPHS2
NPHS2 stomatin family member, podocin
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NR2F2
nuclear receptor subfamily 2 group F member 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NR3C1
nuclear receptor subfamily 3 group C member 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NR3C2
nuclear receptor subfamily 3 group C member 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NUBPL
NUBP iron-sulfur cluster assembly factor, mitochondrial
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NUP107
nucleoporin 107
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NUP133
nucleoporin 133
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NUP160
nucleoporin 160
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NUP205
nucleoporin 205
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NUP37
nucleoporin 37
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NUP85
nucleoporin 85
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
NUP93
nucleoporin 93
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Number of participant deaths Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
Nutritional evaluation (Day 0 and at 6 weeks of intervention). Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
PAX2
paired box 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PLCE1
phospholipase C epsilon 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PODXL
podocalyxin like
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PRDM15
PR/SET domain 15
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
PTPRO
protein tyrosine phosphatase receptor type O
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Physical performance (measured by the Short Physical Performance Battery) Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
Quality-of-life change Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
RALYL
RALY RNA binding protein like
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Respiratory quotient Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
SCNN1A
sodium channel epithelial 1 subunit alpha
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SCNN1B
sodium channel epithelial 1 subunit beta
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SCNN1G
sodium channel epithelial 1 subunit gamma
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SFMBT2
Scm like with four mbt domains 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SGPL1
sphingosine-1-phosphate lyase 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SHISAL1
shisa like 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SLC12A1
solute carrier family 12 member 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SLC12A3
solute carrier family 12 member 3
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SLC6A18
solute carrier family 6 member 18
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SMAD2
SMAD family member 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SMARCAL1
SNF2 related chromatin remodeling annealing helicase 1
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
SYNPO
synaptopodin
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
Strength Functional Functional test — — Emerging ClinicalTrials.gov —
TBC1D8B
TBC1 domain family member 8B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TNFSF15
TNF superfamily member 15
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TNS2
tensin 2
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TRIM8
tripartite motif containing 8
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TRPC6
transient receptor potential cation channel subfamily C member 6
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TSFM
Ts translation elongation factor, mitochondrial
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
TTC21B
tetratricopeptide repeat domain 21B
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
WDR73
WD repeat domain 73
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
WT1
WT1 transcription factor
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
ZNF521
zinc finger protein 521
 Molecular Gene — — Emerging Open Targets UniProt Ensembl Open Targets
effect of PS and PA on Changes in fat mass and Fat free mass (kg) Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
effect of PS and PA on resting energy expenditure (REE) (Kcal/ day) Lab / Clinical Lab value — — Emerging ClinicalTrials.gov —
muscle strength Functional Functional test — — Emerging ClinicalTrials.gov —
skeletal muscle mass index Scales & PROs Clinical scale — — Emerging ClinicalTrials.gov —

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

From opensourcemed.info/chronic-disease — Reversing decline in aging muscles: expected trends, impacts and remedies. Candidates for further study, not approved treatments.

DrugTypePhaseEvidence ScorePrice (UK / US)Trials & literatureSourcesLinks
ACETAZOLAMIDE Repurposing Small molecule Approved Strong 95 UK £3–£8 / 28–56 tabs · US $8–$15 / 30 tabs — ChEMBL ChEMBL Open Targets
AMPHETAMINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
BICALUTAMIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CARBACHOL Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL413 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
CIPROFLOXACIN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
CLOMIPRAMINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIAZEPAM Repurposing Small molecule Approved Strong 95 UK £1–£3 / 28 tabs · US $3–$8 / 30 tabs — ChEMBL ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
EPIRUBICIN Repurposing Small molecule Approved Strong 95 Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP) — ChEMBL ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FLUMAZENIL Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
IMIPRAMINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
INDAPAMIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
INDOMETHACIN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 pubs
View evidence

Published literature

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 pubs
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
LUMASIRAN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
MAFENIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
MECAMYLAMINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
METHAZOLAMIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
METHOXSALEN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
METOPROLOL Repurposing Small molecule Approved Strong 95 UK £2–£4 / 28 tabs · US $4–$9 / 30 tabs — ChEMBL ChEMBL Open Targets
MIANSERIN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NALIDIXIC ACID Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NEDOSIRAN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
NICOTINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
3 pubs
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NORFLOXACIN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
OFLOXACIN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
PHENYTOIN Repurposing Small molecule Approved Strong 95 UK £3–£8 / supply · US $6–$15 / 30 tabs — ChEMBL ChEMBL Open Targets
PRAZOSIN Repurposing Small molecule Approved Strong 95 UK £2–£6 / 28–60 tabs · US $5–$12 / 30–60 tabs
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
SULBACTAM Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
TAZOBACTAM Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
TROGLITAZONE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL172513 Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DARAPLADIB Repurposing Small molecule Phase III Moderate 70 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FENRETINIDE Repurposing Small molecule Phase III Moderate 70 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1200711 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1200946 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1201621 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL191 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL2107910 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL2107951 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL224128 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL283800 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL3137353 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL3221237 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL3545374 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL386630 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ALPRENOLOL Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
AMIFLOXACIN Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
BROLAMFETAMINE Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CARZENIDE Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIFLOXACIN Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIMECAMINE Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ELLAGIC ACID Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ENISOPROST Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FENCAMFAMIN Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FLEROXACIN Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
IDOXIFENE Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
LYSERGIDE Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
MERAFLOXACIN Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
TENAMFETAMINE Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ZIDAPAMIDE Repurposing Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1201498 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1201631 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL136478 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1536 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL256147 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL291962 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
Dioscorea esculenta (Lesser yam extract) OSMF review Herbal Preclinical Emerging 30 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Fish oil (Omega-3 fatty acids) OSMF review Supplement Preclinical Emerging 30 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
8 trials
View evidence

Registry trials

  • NCT04772040 — Impact of Fish Oil Dose on Tissue Content and Function (COMPLETED) NA
  • NCT02617511 — Omega-3 Supplementation and Resistance Training (COMPLETED) NA
  • NCT02103842 — Omega-3 Fatty Acids to Combat Sarcopenia (COMPLETED) PHASE1
  • NCT03462771 — Dietary Supplementation With Omega-3 Fatty Acid in Muscle Response (UNKNOWN) NA
  • NCT05862779 — Effects of Omega-3 and Whey Protein Supplementation on Lean Mass in Older Adults (RECRUITING) NA
  • NCT02779868 — Omega-3 Supplementation in Cervix Cancer Patients Undergoing Chemoradiotherapy (COMPLETED) NA
  • NCT06494566 — Omega-3 Supplementation After Surgical Treatment of Obesity (COMPLETED) EARLY_PHASE1
  • NCT03598413 — PeRioperative Omega Three and the Effect on ImmuNity (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
High-protein diet (>=1.2 g/kg/day) OSMF review Lifestyle Preclinical Emerging 30 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
5 trials
View evidence

Registry trials

  • NCT03860194 — Effects of Dietary Supplements on Sarcopenic Elders (COMPLETED) NA
  • NCT02379026 — Lifestyle Modifications for the Treatment of Sarcopenic Obesity (UNKNOWN) NA
  • NCT02371278 — Leucine Co-ingestion and Myofibrillar Protein Synthesis in Older Adults (COMPLETED) NA
  • NCT05912309 — Effects of Time-restricted Eating and Exercise Training on Skeletal Muscle Mass Quantity, Quality and Function in Postmenopausal Women With Overweight and Obesity (UNKNOWN) NA
  • NCT03024125 — High vs Normal Protein Diets, Resistance Exercise, Lean Mass and Strength Gains (UNKNOWN) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Leucine supplementation OSMF review Supplement Preclinical Emerging 30 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
8 trials 3 Cochrane 2 Meta-analysis 2 Trial pubs 2 RCT
View evidence

Registry trials

  • NCT03860194 — Effects of Dietary Supplements on Sarcopenic Elders (COMPLETED) NA
  • NCT06971822 — Assessing the Impact of a Leucine Enriched Whey Protein vs Isonitrogenous Whey on Muscle Protein Synthetic Responses in the Rested and Acute Post Exercise States in Older Adults (RECRUITING) NA
  • NCT04309292 — Protein and Skeletal Muscle in Older Twins: Role of the Gut Microbiome (COMPLETED) NA
  • NCT06991855 — Effects of Nutritional Supplementation of Leucine and Polyunsaturated Fatty Acids on Muscle Health in the Elderly (RECRUITING) NA
  • NCT01757340 — Calorie Restriction With Leucine Supplementation (COMPLETED) NA
  • NCT03815201 — Protein Supplementation and Muscle Function in the Elderly (UNKNOWN) NA
  • NCT00807508 — Leucine Supplementation in Elderly Men (COMPLETED) PHASE1, PHASE2
  • NCT06121492 — Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia (ENROLLING_BY_INVITATION) PHASE3

Published literature

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Losartan OSMF review Small molecule Preclinical Emerging 30 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 trials
View evidence

Registry trials

  • NCT01989793 — A Study of Muscle Strength Maintenance in Older Adults (COMPLETED) PHASE2

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Metformin OSMF review Small molecule Preclinical Emerging 30 UK £1–£3 / 28–56 tabs · US $4–$10 / 30–90 tabs
1 trials 1 Cochrane 1 Meta-analysis 4 Trial pubs 4 RCT
View evidence

Registry trials

  • NCT01804049 — Metformin and Muscle in Insulin-resistant Older Veterans (COMPLETED) PHASE1, PHASE2

Published literature

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Resistance training (Strength training) OSMF review Lifestyle Preclinical Emerging 30 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
8 trials
View evidence

Registry trials

  • NCT07601321 — BCW-Based Resistance Training for Community-Dwelling Sarcopenia Patients (NOT_YET_RECRUITING) NA
  • NCT05497687 — Strength-building Lifestyle-integrated Intervention (COMPLETED) NA
  • NCT05778136 — Lung Cancer, Exercise and Force Development (UNKNOWN) NA
  • NCT03266575 — Pulmonary Rehabilitation in End-Stage Liver Disease (TERMINATED) NA
  • NCT05194397 — Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors (RECRUITING) PHASE2
  • NCT05691166 — Reducing Falls With Progressive Resistance Training for the Oldest Old Adults With Sarcopenia (ACTIVE_NOT_RECRUITING) NA
  • NCT06480643 — Effect of Exercise Type on Muscle Quality in Patients With OA, SARC and RA: an Explorative Study (NOT_YET_RECRUITING) NA
  • NCT02873676 — Prevalence and Effect of Lifestyle Modification on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia (UNKNOWN) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Selenium supplementation OSMF review Supplement Preclinical Emerging 30 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 trials
View evidence

Registry trials

  • NCT05324475 — Maintaining Immune and Mitochondrial Functions in Old Adults With SAfe Nutrition. (RECRUITING) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
ALBUMIN HUMAN Biologic Preclinical Emerging 15 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — Open Targets ChEMBL Open Targets
CHEMBL2003538 Small molecule Preclinical Emerging 15 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL454801 Small molecule Preclinical Emerging 15 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DrugTypePhaseEvidence ScorePrice (UK / US)Trials & literatureSourcesLinks
CHEMBL172513 Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1200711 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1200946 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1201621 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL191 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL2107910 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL2107951 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL224128 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL283800 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL3137353 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL3221237 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL3545374 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL386630 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1201498 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1201631 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL136478 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL1536 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL256147 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL291962 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL413 Small molecule Phase I Emerging 35 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
ALBUMIN HUMAN Biologic Preclinical Emerging 15 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — Open Targets ChEMBL Open Targets
CHEMBL2003538 Small molecule Preclinical Emerging 15 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CHEMBL454801 Small molecule Preclinical Emerging 15 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DrugTypePhaseEvidence ScorePrice (UK / US)Trials & literatureSourcesLinks
ACETAZOLAMIDE Repurposing via ACTN4 Small molecule Approved Strong 95 UK £3–£8 / 28–56 tabs · US $8–$15 / 30 tabs — ChEMBL ChEMBL Open Targets
AMPHETAMINE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
BICALUTAMIDE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CARBACHOL Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CIPROFLOXACIN Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
CLOMIPRAMINE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIAZEPAM Repurposing via ACTN4 Small molecule Approved Strong 95 UK £1–£3 / 28 tabs · US $3–$8 / 30 tabs — ChEMBL ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
EPIRUBICIN Repurposing via ACTN4 Small molecule Approved Strong 95 Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP) — ChEMBL ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FLUMAZENIL Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
IMIPRAMINE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
INDAPAMIDE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
INDOMETHACIN Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 pubs
View evidence

Published literature

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 pubs
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
LUMASIRAN Repurposing via AGXT Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
MAFENIDE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
MECAMYLAMINE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
METHAZOLAMIDE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
METHOXSALEN Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
METOPROLOL Repurposing via ACTN4 Small molecule Approved Strong 95 UK £2–£4 / 28 tabs · US $4–$9 / 30 tabs — ChEMBL ChEMBL Open Targets
MIANSERIN Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NALIDIXIC ACID Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NEDOSIRAN Repurposing via AGXT Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 DGIdb —
NICOTINE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
3 pubs
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
NORFLOXACIN Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
OFLOXACIN Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
PHENYTOIN Repurposing via ACTN4 Small molecule Approved Strong 95 UK £3–£8 / supply · US $6–$15 / 30 tabs — ChEMBL ChEMBL Open Targets
PRAZOSIN Repurposing via ACTN4 Small molecule Approved Strong 95 UK £2–£6 / 28–60 tabs · US $5–$12 / 30–60 tabs
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
SIROLIMUS Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
SULBACTAM Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
TAZOBACTAM Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 ChEMBL ChEMBL Open Targets
TROGLITAZONE Repurposing via ACTN4 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DARAPLADIB Repurposing via ACTN4 Small molecule Phase III Moderate 70 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FENRETINIDE Repurposing via ACTN4 Small molecule Phase III Moderate 70 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ALPRENOLOL Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
AMIFLOXACIN Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
BROLAMFETAMINE Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
CARZENIDE Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIFLOXACIN Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DIMECAMINE Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ELLAGIC ACID Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ENISOPROST Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FENCAMFAMIN Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
FLEROXACIN Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
IDOXIFENE Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
LYSERGIDE Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
MERAFLOXACIN Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
TENAMFETAMINE Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
ZIDAPAMIDE Repurposing via ACTN4 Small molecule Phase II Emerging 45 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL ChEMBL Open Targets
DrugTypePhaseEvidence ScorePrice (UK / US)Trials & literatureSourcesLinks
Dioscorea esculenta (Lesser yam extract) OSMF review Herbal Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Fish oil (Omega-3 fatty acids) OSMF review Supplement Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials
View evidence

Registry trials

  • NCT04772040 — Impact of Fish Oil Dose on Tissue Content and Function (COMPLETED) NA
  • NCT02617511 — Omega-3 Supplementation and Resistance Training (COMPLETED) NA
  • NCT02103842 — Omega-3 Fatty Acids to Combat Sarcopenia (COMPLETED) PHASE1
  • NCT03462771 — Dietary Supplementation With Omega-3 Fatty Acid in Muscle Response (UNKNOWN) NA
  • NCT05862779 — Effects of Omega-3 and Whey Protein Supplementation on Lean Mass in Older Adults (RECRUITING) NA
  • NCT02779868 — Omega-3 Supplementation in Cervix Cancer Patients Undergoing Chemoradiotherapy (COMPLETED) NA
  • NCT06494566 — Omega-3 Supplementation After Surgical Treatment of Obesity (COMPLETED) EARLY_PHASE1
  • NCT03598413 — PeRioperative Omega Three and the Effect on ImmuNity (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
High-protein diet (>=1.2 g/kg/day) OSMF review Lifestyle Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
5 trials
View evidence

Registry trials

  • NCT03860194 — Effects of Dietary Supplements on Sarcopenic Elders (COMPLETED) NA
  • NCT02379026 — Lifestyle Modifications for the Treatment of Sarcopenic Obesity (UNKNOWN) NA
  • NCT02371278 — Leucine Co-ingestion and Myofibrillar Protein Synthesis in Older Adults (COMPLETED) NA
  • NCT05912309 — Effects of Time-restricted Eating and Exercise Training on Skeletal Muscle Mass Quantity, Quality and Function in Postmenopausal Women With Overweight and Obesity (UNKNOWN) NA
  • NCT03024125 — High vs Normal Protein Diets, Resistance Exercise, Lean Mass and Strength Gains (UNKNOWN) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Leucine supplementation OSMF review Supplement Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 3 Cochrane 2 Meta-analysis 2 Trial pubs 2 RCT
View evidence

Registry trials

  • NCT03860194 — Effects of Dietary Supplements on Sarcopenic Elders (COMPLETED) NA
  • NCT06971822 — Assessing the Impact of a Leucine Enriched Whey Protein vs Isonitrogenous Whey on Muscle Protein Synthetic Responses in the Rested and Acute Post Exercise States in Older Adults (RECRUITING) NA
  • NCT04309292 — Protein and Skeletal Muscle in Older Twins: Role of the Gut Microbiome (COMPLETED) NA
  • NCT06991855 — Effects of Nutritional Supplementation of Leucine and Polyunsaturated Fatty Acids on Muscle Health in the Elderly (RECRUITING) NA
  • NCT01757340 — Calorie Restriction With Leucine Supplementation (COMPLETED) NA
  • NCT03815201 — Protein Supplementation and Muscle Function in the Elderly (UNKNOWN) NA
  • NCT00807508 — Leucine Supplementation in Elderly Men (COMPLETED) PHASE1, PHASE2
  • NCT06121492 — Oral Branched-chain Amino Acid Supplementation for Cirrhotic Patients With Sarcopenia (ENROLLING_BY_INVITATION) PHASE3

Published literature

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Losartan OSMF review Small molecule Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 trials
View evidence

Registry trials

  • NCT01989793 — A Study of Muscle Strength Maintenance in Older Adults (COMPLETED) PHASE2

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Metformin OSMF review Small molecule Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 trials 1 Cochrane 1 Meta-analysis 4 Trial pubs 4 RCT
View evidence

Registry trials

  • NCT01804049 — Metformin and Muscle in Insulin-resistant Older Veterans (COMPLETED) PHASE1, PHASE2

Published literature

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Resistance training (Strength training) OSMF review Lifestyle Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials
View evidence

Registry trials

  • NCT07601321 — BCW-Based Resistance Training for Community-Dwelling Sarcopenia Patients (NOT_YET_RECRUITING) NA
  • NCT05497687 — Strength-building Lifestyle-integrated Intervention (COMPLETED) NA
  • NCT05778136 — Lung Cancer, Exercise and Force Development (UNKNOWN) NA
  • NCT03266575 — Pulmonary Rehabilitation in End-Stage Liver Disease (TERMINATED) NA
  • NCT05194397 — Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors (RECRUITING) PHASE2
  • NCT05691166 — Reducing Falls With Progressive Resistance Training for the Oldest Old Adults With Sarcopenia (ACTIVE_NOT_RECRUITING) NA
  • NCT06480643 — Effect of Exercise Type on Muscle Quality in Patients With OA, SARC and RA: an Explorative Study (NOT_YET_RECRUITING) NA
  • NCT02873676 — Prevalence and Effect of Lifestyle Modification on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia (UNKNOWN) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation
Selenium supplementation OSMF review Supplement Preclinical Emerging 30 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 trials
View evidence

Registry trials

  • NCT05324475 — Maintaining Immune and Mitochondrial Functions in Old Adults With SAfe Nutrition. (RECRUITING) NA

CT.gov search · Cochrane · PubMed

 OSMF Chronic Disease Review OSMF Review Citation

Natural Products

73 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

DrugTypePhaseEvidence ScorePrice (UK / US)Trials & literatureSourcesLinks
Vitamin D3 Natural product Nutraceutical Approved Emerging 19 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 11 Trial pubs
View evidence

Registry trials

  • NCT02402608 — Efficacy of Dietary Supplementation and Physical Activity in Sarcopenic Elderly (COMPLETED) NA
  • NCT02717819 — The Importance of Additional Protein to Benefit More From Training During and After Hospitalization (COMPLETED) NA
  • NCT06791044 — 25(OH)-Vitamin D and Its Association With Structural and Functional Parameters in Hospitalized Patients With Neurological Diseases (RECRUITING) NA
  • NCT00104572 — Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial. (COMPLETED) PHASE2
  • NCT06287502 — Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis (COMPLETED) NA
  • NCT04756856 — Muscle-targeted Nutritional Therapy for the Recovery From COVID-19 (TERMINATED) NA
  • NCT01850251 — Effects of a Supplement Enriched in Hydroxymethylbutyrate and Vitamin D on Muscle Strength in Hip Fracture (TERMINATED) PHASE4
  • NCT04399291 — Vitamin D Status and Bone Health of Older Adults in Care Facilities (SUSPENDED)

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov PubChem
Omega-3 Fatty Acids Natural product Nutraceutical Phase I Emerging 19 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 2 Cochrane 2 Meta-analysis 6 RCT
View evidence

Registry trials

  • NCT06287502 — Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis (COMPLETED) NA
  • NCT06015971 — Omega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer (RECRUITING) NA
  • NCT01308957 — Fish Oil and Muscle Function (COMPLETED) NA
  • NCT02374268 — Intervention Assessing the Role of Exercise Program and Nutrition Supplement for Sarcopenia (COMPLETED) NA
  • NCT03598413 — PeRioperative Omega Three and the Effect on ImmuNity (COMPLETED) NA
  • NCT07653737 — Immunonutrition for Prehabilitation of Patients With Colorectal Cancer Before Surgery (COMPLETED) NA
  • NCT06494566 — Omega-3 Supplementation After Surgical Treatment of Obesity (COMPLETED) EARLY_PHASE1
  • NCT05869526 — A Comparison of the Effects of Krill Oil and Fish Oil Supplementation on Muscle Function in Older Adults (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov PubChem
Whey Protein Natural product Nutraceutical Phase II Moderate 19 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials
View evidence

Registry trials

  • NCT02402608 — Efficacy of Dietary Supplementation and Physical Activity in Sarcopenic Elderly (COMPLETED) NA
  • NCT07038655 — Investigating the Digestibility, Bioavailability and Utilisation of Varied Combined Protein Sources in Older Males Using a Dual Stable Isotope Tracer Technique (COMPLETED) NA
  • NCT05700058 — Assessing the Dose-response of Muscle Protein Synthesis to "Super-whey" in Older Adults (RECRUITING) NA
  • NCT02717819 — The Importance of Additional Protein to Benefit More From Training During and After Hospitalization (COMPLETED) NA
  • NCT01986842 — Habitual Protein Intake and Muscle Protein Synthesis (COMPLETED) NA
  • NCT03417531 — Sarcopenia Prevention With a Targeted Exercise and Protein Supplementation Program (COMPLETED) NA
  • NCT04756856 — Muscle-targeted Nutritional Therapy for the Recovery From COVID-19 (TERMINATED) NA
  • NCT01757340 — Calorie Restriction With Leucine Supplementation (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 Examine.com Examine.com
Soy Protein Natural product Nutraceutical Phase II Moderate 19 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 3 Trial pubs
View evidence

Registry trials

  • NCT07038655 — Investigating the Digestibility, Bioavailability and Utilisation of Varied Combined Protein Sources in Older Males Using a Dual Stable Isotope Tracer Technique (COMPLETED) NA
  • NCT04951843 — Koji Product Supplementation' s Study (COMPLETED) NA
  • NCT05869305 — Efficacy and Safety of Protein Product in Volunteers With Sarcopenia (UNKNOWN) NA
  • NCT02529917 — The Benefits of Hemp Protein Supplementation During Resistance Training (COMPLETED) NA
  • NCT01062711 — Dose Response of Whey and Soy Protein Ingestion With and Without Resistance Exercise in Elderly Men (COMPLETED) NA
  • NCT01883674 — Milk and Milk-produce to Counteract the Loss of Muscle Mass and Function in Exercising Older Adults. (COMPLETED) NA
  • NCT01900548 — Effect of Intake of Whey Protein in Elderly Osteopenic Patients. Implications for Metabolism and Physical Function. (COMPLETED) NA
  • NCT05243472 — Impact of Protein-Enriched Lacto-Vegetarian Soup on Muscle Mass and Muscle Strength Among Older Adults (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 Examine.com Examine.com
Iron Natural product Nutraceutical Approved Emerging 16 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
5 trials 3 Trial pubs
View evidence

Registry trials

  • NCT00891696 — Nutritional and Contractile Regulation of Muscle Growth (COMPLETED) PHASE1
  • NCT05485402 — Dietary Strategy to Tackle Sarcopenia in Early Elderly Subjects (FOOP-Sarc) (COMPLETED) NA
  • NCT00690534 — Insulin and Sarcopenia in the Elderly (COMPLETED) PHASE1
  • NCT07162090 — Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients (NOT_YET_RECRUITING) PHASE4
  • NCT05324475 — Maintaining Immune and Mitochondrial Functions in Old Adults With SAfe Nutrition. (RECRUITING) NA

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov PubChem
Creatine Natural product Amino acid Phase II Emerging 16 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 1 Cochrane 10 Trial pubs
View evidence

Registry trials

  • NCT02062086 — Estimation of Muscle Mass in Older Adults Using Deuterated Creatine (TERMINATED) NA
  • NCT07275996 — Neuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty (ACTIVE_NOT_RECRUITING) NA
  • NCT07463092 — Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy (RECRUITING) NA
  • NCT03530202 — Effects of High-velocity Resistance Training and Creatine Supplementation in Healthy Aging Males (UNKNOWN) PHASE2
  • NCT05008562 — How COVID-19 Effects to Muscle Mass Change ın ICU? (COMPLETED)
  • NCT00473902 — Older Adult Training Study With Creatine and CLA (COMPLETED) NA
  • NCT04058002 — Project Arthritis Recovering Quality of Life Through Education 70+ (UNKNOWN) NA
  • NCT07625202 — Creatine Supplementation During GLP-1a Therapy (RECRUITING) NA

CT.gov search · Cochrane · PubMed

 ClinicalTrials.gov PubChem
Medium-Chain Triglycerides Natural product Nutraceutical Phase I Moderate 13 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 trials
View evidence

Registry trials

  • NCT06376266 — Assessment of the Intervention Effectiveness of Branched-chain Amino Acids(BCAA) Combined With Medium-chain Fatty Acid(MCFA) Products in Sarcopenia Among Middle-aged and Elderly Individuals (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 Examine.com Examine.com
Vitamin D3 Natural product Nutraceutical Approved Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 11 Trial pubs
View evidence

Registry trials

  • NCT02402608 — Efficacy of Dietary Supplementation and Physical Activity in Sarcopenic Elderly (COMPLETED) NA
  • NCT02717819 — The Importance of Additional Protein to Benefit More From Training During and After Hospitalization (COMPLETED) NA
  • NCT06791044 — 25(OH)-Vitamin D and Its Association With Structural and Functional Parameters in Hospitalized Patients With Neurological Diseases (RECRUITING) NA
  • NCT00104572 — Effects of Aromatase Inhibition Versus Testosterone in Older Men With Low Testosterone: Randomized-Controlled Trial. (COMPLETED) PHASE2
  • NCT06287502 — Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis (COMPLETED) NA
  • NCT04756856 — Muscle-targeted Nutritional Therapy for the Recovery From COVID-19 (TERMINATED) NA
  • NCT01850251 — Effects of a Supplement Enriched in Hydroxymethylbutyrate and Vitamin D on Muscle Strength in Hip Fracture (TERMINATED) PHASE4
  • NCT04399291 — Vitamin D Status and Bone Health of Older Adults in Care Facilities (SUSPENDED)

CT.gov search · Cochrane · PubMed

 PubChem
Omega-3 Fatty Acids Natural product Nutraceutical Phase I Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 2 Cochrane 2 Meta-analysis 6 RCT
View evidence

Registry trials

  • NCT06287502 — Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis (COMPLETED) NA
  • NCT06015971 — Omega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer (RECRUITING) NA
  • NCT01308957 — Fish Oil and Muscle Function (COMPLETED) NA
  • NCT02374268 — Intervention Assessing the Role of Exercise Program and Nutrition Supplement for Sarcopenia (COMPLETED) NA
  • NCT03598413 — PeRioperative Omega Three and the Effect on ImmuNity (COMPLETED) NA
  • NCT07653737 — Immunonutrition for Prehabilitation of Patients With Colorectal Cancer Before Surgery (COMPLETED) NA
  • NCT06494566 — Omega-3 Supplementation After Surgical Treatment of Obesity (COMPLETED) EARLY_PHASE1
  • NCT05869526 — A Comparison of the Effects of Krill Oil and Fish Oil Supplementation on Muscle Function in Older Adults (COMPLETED) NA

CT.gov search · Cochrane · PubMed

 PubChem
Magnesium Natural product Nutraceutical Approved Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 3 Cochrane 3 Meta-analysis 4 Trial pubs 4 RCT
View evidence

Registry trials

  • NCT07567963 — Magnesium Supplementation as a Nutritional Intervention in Sarcopenia (NOT_YET_RECRUITING) NA
  • NCT05348694 — OsteoPreP: Food Supplements for Postmenopausal Bone Health (UNKNOWN) PHASE4
  • NCT06851676 — Functional and Metabolic Effects of Fonte Fausta® Water on Bone and Muscle Health in Osteoporotic Patients (RECRUITING) NA
  • NCT01775111 — Influence of Strength Training and Protein Supplementation on Fitness of Institutionalized Elderly (UNKNOWN) NA
  • NCT05872360 — To Investigate Effects of Amway Bundle Combination of Products on Osteoarthritis & Sarcopenia (COMPLETED) NA
  • NCT04354896 — The Effect of Thyroid Hormone Therapy on Muscle Mass and Function in Older Adults With Subclinical Hypothyroidism (COMPLETED) PHASE4
  • NCT05730985 — From the Gut to the Strut: Reducing Inflammation for Healthy Muscles (UNKNOWN) NA
  • NCT06248437 — Prototype of Innovative Food Product to Improve Respiratory and Peripheral Muscle Function in Humans (COMPLETED)

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
Vitamin B12 Natural product Nutraceutical Preclinical Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
3 trials 1 Trial pubs 1 RCT
View evidence

Registry trials

  • NCT01775111 — Influence of Strength Training and Protein Supplementation on Fitness of Institutionalized Elderly (UNKNOWN) NA
  • NCT05324475 — Maintaining Immune and Mitochondrial Functions in Old Adults With SAfe Nutrition. (RECRUITING) NA
  • NCT06248437 — Prototype of Innovative Food Product to Improve Respiratory and Peripheral Muscle Function in Humans (COMPLETED)

CT.gov search · Cochrane · PubMed

 PubChem
N-Acetylcysteine Natural product Amino acid Preclinical Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 Cochrane
View evidence

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
Taurine Natural product Amino acid Preclinical Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
2 trials
View evidence

Registry trials

  • NCT05415176 — Taurine Supplementation Associated or Not With Exercise: Effect on Browning of White Adipose Tissue in Elderly Women With Sarcopenic Obesity (UNKNOWN) NA
  • NCT04516421 — Protein Supplementation Intervention for Improving Muscle Mass and Physical Performance in Older People With Sarcopenia (UNKNOWN) NA

CT.gov search · Cochrane · PubMed

 PubChem
Nicotinamide Mononucleotide Natural product Food compound Preclinical Moderate 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 Examine.com PubChem Examine.com
Curcumin Natural product Food compound Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 Cochrane 2 Trial pubs
View evidence

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
L-Citrulline Natural product Amino acid Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
2 trials 2 Trial pubs 2 RCT
View evidence

Registry trials

  • NCT03694964 — Severe Chronic Respiratory Failure and Citrulline (UNKNOWN) NA
  • NCT02417428 — Citrulline Supplementation Combined With Exercise: Effect on Muscle Function in Elderly People (CITEX Study) (COMPLETED) NA

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
Resveratrol Natural product Food compound Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
3 trials
View evidence

Registry trials

  • NCT06585865 — Strength Training and Resveratrol (RECRUITING) NA
  • NCT05981053 — Biological Effects in Consumers of Resveratrol-enriched Wine (COMPLETED)
  • NCT02001831 — Multi-ingredient Nutrition Supplement in Older Adults (UNKNOWN) NA

Published literature

CT.gov search · Cochrane · PubMed

 PubChem
Ginseng Natural product Botanical Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 trials 1 RCT
View evidence

Registry trials

  • NCT05919368 — The Shape Regulation Mechanism of Yam Pill on Patients With Sarcopenia Based on Intestine-muscle-brain Axis (UNKNOWN) NA

Published literature

CT.gov search · Cochrane · PubMed

 —
Creatine Natural product Amino acid Phase II Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 1 Cochrane 10 Trial pubs
View evidence

Registry trials

  • NCT02062086 — Estimation of Muscle Mass in Older Adults Using Deuterated Creatine (TERMINATED) NA
  • NCT07275996 — Neuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty (ACTIVE_NOT_RECRUITING) NA
  • NCT07463092 — Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy (RECRUITING) NA
  • NCT03530202 — Effects of High-velocity Resistance Training and Creatine Supplementation in Healthy Aging Males (UNKNOWN) PHASE2
  • NCT05008562 — How COVID-19 Effects to Muscle Mass Change ın ICU? (COMPLETED)
  • NCT00473902 — Older Adult Training Study With Creatine and CLA (COMPLETED) NA
  • NCT04058002 — Project Arthritis Recovering Quality of Life Through Education 70+ (UNKNOWN) NA
  • NCT07625202 — Creatine Supplementation During GLP-1a Therapy (RECRUITING) NA

CT.gov search · Cochrane · PubMed

 PubChem
Berberine Natural product Botanical Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 PubChem
Sulforaphane Natural product Food compound Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — PubChem
Spirulina Natural product Nutraceutical Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Chamomile Natural product Botanical Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Fenugreek Natural product Botanical Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Ginkgo Biloba Natural product Botanical Preclinical Emerging 2 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Manzamine a Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ChEMBL ChEMBL PubChem ChEMBL
Nifedipine Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ChEMBL ChEMBL PubChem ChEMBL
Nimodipine Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ChEMBL ChEMBL PubChem ChEMBL
1H-indol-3-ylmethyl(dimethyl)amine Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ChEMBL ChEMBL PubChem ChEMBL
Nicotinamide Mononucleotide Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
No indexed hits
View evidence

CT.gov search · Cochrane · PubMed

 Examine.com PubChem Examine.com
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methylol-tetrahydrofuran-2-yl]pyridin-1-ium-3-carboxamide Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ClinicalTrials.gov PubChem
(2S)-2-amino-4-methyl-valeric acid Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ClinicalTrials.gov PubChem
(7-chloro-4-hydroxy-5-phenyl-3H-1,4-benzodiazepin-2-ylidene)-methyl-amine Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ClinicalTrials.gov PubChem
3-hydroxy-3-methyl-butyric acid Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — ClinicalTrials.gov PubChem
Whey Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Ginseng (Korean) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Ginsenosides Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Lactobacillus Plantarum Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Polyphenols Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Rutin Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Icariin Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Goji Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Puerarin Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Nuts: All Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Leucine Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — PubChem
Miso Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Krill Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Olive Leaf Extract Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Chlorella (Algae) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Beta Sitosterol Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Blue Honeysuckle Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Baicalein Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Betaine Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Propolis: Brazillian Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
CLA (Conjugated Linoleic Acid) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Emodin Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Ginseng (American) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Hesperidin Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — PubChem
Lactobacillus Paracasei Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Loquat Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Psilocybin Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Luteolin Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — PubChem
Oligonol Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Lactoferrin Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — PubChem
GABA (Gamma-Aminobutyric Acid) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Butyrate Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — PubChem
Astaxanthin Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — PubChem
Carotenoids Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Royal Jelly Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Propolis: Bee Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Formononetin Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Burdock Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —
Flavonoids Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) — —

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.